Forbion Capital Partners is a venture capital firm established in 2007. The firm was founded as a specialized private equity branch of ABN AMRO Capital, which is associated with the Netherlands-based ABN AMRO Bank. The firm’s headquarters is located in Naarden, Netherlands, with additional offices located in Munich, Germany; Tel Aviv, Israel; and Boston, Massachusetts.
Forbion Capital Partners also has a joint venture to manage seed and early-stage funds with BioGeneration Ventures. As of February 2019, Forbion Capital Partners is managing 21 companies in its portfolio and has sold off its shares in 58 companies. It has most recently funded Inflazome in November 2018, a company that specializes in developing oral drugs to manage chronic inflammatory diseases.
Forbion Capital Partners focuses on funding companies that are established in Europe (especially Austria, Germany, Switzerland, and Netherlands), Israel, and North America. The firm provides funding for companies in the field of life sciences and bio-medical technology. It gives capital to companies in various stages of development, from seed to growth stage. With its latest funding round in July 2018, the firm has managed to collect $1.2 billion in total. In the July 2018 round, the firm succeeding in amassing €360 million .